Non-viral vectors continue to be an attractive alternative to viral vectors due to their safety, versatility and ease of preparation and scale-up. Over the past few years, investigators have been successful in developing gene carriers that can be targeted to the disease site. Several different delivery vectors for systemic use have been developed by different groups for plasmid DNA and oligonucleotide. Most of them are designed for targeted tumor therapy. The mechanism of inflammatory toxicity, the major toxicity of cationic lipoplex, has been studied and managed. In this review, we focus on the progress made over the last 2 years. We also discuss some future prospects for gene delivery.
In brief Progress
PEGylated nanoparticles with multiple components are the most promising non-viral vectors for systemic delivery. Low-volume injection of naked DNA via inferior vena cava introduced significant gene expression in the kidneys. Sterically stabilized lipoplex/polyplexes showed high tumor uptake and transgene expression. Reduction of the alkyl chain length of the PEG-lipid from C18 to C16 reduced the immune response against PEGylated liposomes. 2 0 -O-methyl phosphorothioate oligonucleotide mixed with Pluronic F127 was successfully delivered to all skeletal muscles by i.v. injection. Cholesterol-modified small interfering RNA (siRNA) showed increased stability and gene silencing activity. Atelocollagen/siRNA complexes showed great antitumor activity via RNAi. Protamine-Fab antibody fusion protein delivered siRNA predominantly to target cells and silenced the target genes. Targeted, PEGylated polyplexes/immunoliposomes provided high tumor uptake for siRNA and marked antitumor activity via RNAi. SNALPs targeted to the livers and showed RNAimediated gene silencing in hepatitis B and hypercholesteroldemia models. Certain proteins involved in lung targeting and reduced liver uptake in sequential injection of cationic liposome and plasmid DNA. Sequence-dependent stimulation of the immune response by synthetic siRNA can be abrogated by incorporation of 2 0 OMe uridine or guanosine nucleosides into one strand. Intratumoral delivery of IL-2 plasmid DNA showed encouraging results in head and neck cancer patients in a phase I trial.
PEGylated nanoparticles with multiple components are the most promising non-viral vector for systemic delivery
Investigators in non-viral vector development have introduced a variety of strategies to overcome barriers for gene delivery. [1] [2] [3] These include (a) polynucleotide degradation in the extracellular space, (b) internalization of the carrier, (c) intracellular trafficking from the endosome to the lysosome and the escape of the polynucleotide from the endosome, (d) dissociation of polynucleotide from the carrier and (e) entry of the polynucleotide into the nucleus. For systemic in vivo applications, further factors should be considered, including physicochemical properties that affect stability in the blood (i.e. particle size and zeta potential of the vector) and the immune system (i.e. reticuloendothelial system capture of the vector).
Owing to their multiple components, viruses are able to achieve a multipronged approach to infection. 1 This has led investigators to design a multifunctional nonviral vector that can overcome the different barriers. Table 1 summarizes the idea of the design. Carrier molecules, such as protamine and polyethyleneimine (PEI), which can condense polynucleotides and provide protection against nucleases, are the major components of the delivery system. However, the positively charged DNA-cationic carrier complex tends to aggregate when injected into the blood and lacks tissue specificity. PEGylation of the cationic carrier can shield the positive charge, prevent aggregation and increase the circulation time in the blood. Furthermore, PEGylated nanocarriers have been shown to accumulate in highly vasculated tissues, referred to as the enhanced permeability and retention (EPR). 13 To further increase the cellular uptake, ligands are tethered to the distal end of the PEG to trigger receptor-mediated endocytosis after the vector is recognized by a cell surface receptor. When entrapped in an acidic endosomal environment following endocytosis, components in the carrier that possess a proton sponge or endosomolytic activity will cause endosome rupture, thereby releasing the encapsulated polynucleotide. The nuclear entry of the plasmid DNA is another barrier that can be overcome by incorporation of nuclear localization signal (NLS) peptides in the formulations.
Although different approaches have been developed to overcome the barriers for gene delivery, non-viral vectors are still inefficient compared to viral vectors, suggesting that there are still some missing parts that need to be addressed. Advanced technologies, such as real-time live cell imaging, can be applied to intracellular trafficking studies, which will benefit the design of new formulations.
Plasmid DNA delivery
Low-volume injection of naked DNA via inferior vena cava introduced significant gene expression in the kidneys Hydrodynamic gene delivery, the first systemic delivery method for naked DNA, is a rapid injection of a large volume of naked DNA solution (e.g. 5 mg plasmid DNA injected in 5-8 s in 1.6 ml saline solution for a 20 g mouse) via the tail vein. This technique can induce potent gene transfer predominantly in the liver. Wu et al.
14 have recently reported another delivery method for naked DNA. They injected naked DNA via the inferior vena cava (i.v.c.) (100 mg DNA in 0.2 ml buffer for 6 to 8-week-old mice) and found that gene expression mainly localized in the proximal tubular epithelial cells of the corticomeduallary region of the kidney. DNA was delivered to the renal cell membrane 10 min after IVC injection and was internalized into the cytoplasm and nuclei by 30 min. Stable b-galactosidase gene expression could be detected up to 35 days without any notable toxicity or adverse pathological effects. They also demonstrated that the IVC gene delivery method could transfect more than 70% of renal carcinoma cells inoculated in the kidneys of severe combined immunodeficiency mice. The hypothesis is that DNA is first carried to the kidney via the renal vein when plasmid DNA is injected via the IVC. This method may be applied clinically, as the circulatory system and the location of major organs in mice are similar to that of humans and only a small injection volume is needed. However, the predominant cytosolic localization of injected DNA suggests that introduction of DNA nuclear targeting sequences to plasmid DNA could increase transfection efficiency. 2 Sterically stabilized lipoplex/polyplexes showed high tumor uptake and transgene expression Yu et al. 5 developed a sterically stabilized immunolipoplex for systemic administration. Instead of using precoated liposomes for immunolipoplex preparation 
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and thereby losing the charge interaction between the DNA and the 'shielded' liposome, they employed a postmodification strategy. The lipoplex was formed first, and then sequentially post-conjugated with a functional polyethylene glycol (PEG) chain and then the antibody to the transferrin receptor. The resulting particles had a mean size of 90 nm and a zeta potential of 17 mV. After i.v. injection of the immunolipoplex into tumor-bearing mice, high levels of transgene expression were detected in the tumor, whereas relatively low transfection activity was found in the liver. The results showed that tumor targeting with high specificity could be achieved by the complex in the presence of PEGylation and antibody conjugation. Recently, they showed that the formulation can also be applied for targeted delivery of siRNA to primary and metastatic tumors 15 however, no efficacy data were shown. The challenge for the technique is to prevent the aggregation of DNA and cationic liposome when preparing lipoplex before PEGylation in the scaleup process.
Polyplexes are another powerful non-viral vector but also share the same disadvantages of lipoplexes. It is known that PEGylation of polyplexes prevents aggregation, lowers their toxicity, increases the circulation time and improves the targeted gene transfer. 16 Unfortunately, PEGylation also significantly reduces their transfection efficiency. Although ligand attachment can increase the gene delivery efficiency of the PEGylated polyplex, it is still not comparable to uncoated polyplex owing to the stable shielding of PEG. Walker et al. 9 linked PEG with a polycation via pyridylhydrazines that can be cleaved at low pH (B5) in the endosomal environment. They demonstrated that the novel polymer was 90% hydrolyzed at pH 5 in 10 min, whereas it had a longer half-life of 1.5 h at pH 7.4. The reversibly shielded polyplex showed complete deshielding within 1 h at pH 5, whereas the shield remained after 4 h at pH 7.4. After i.v. injection into tumor-bearing mice, reversibly shielded polyplexes showed higher gene transfection efficiency in tumors compared to polyplexes or stably shielded polyplexes. However, high gene expression in the liver and the lung was also detected, indicating that the shielding was not stable in the blood. To assess this possibility, a tissue distribution study of plasmid DNA is recommended. If the shielding is stable, the distribution pattern in the major organs of reversibly shielded polyplexes should be similar to stably shielded ones. DNA release from the polyplexes is potentially problematic; development of a new polymer with a triggered release mechanism remains a challenge.
Kaul and Amiji 17,8 utilized a water-ethanol solvent displacement technique to entrap plasmid DNA into PEGylated nanoparticles of approximately 200 nm in diameter. Instead of using charge interaction to encapsulate DNA, they gradually added ethanol into the aqueous mixture of gelatin-PEG and DNA under controlled stirring conditions and precipitated the nanopaticles. Crosslinking of the nanoparticles was performed by addition of glyoxal to stabilize the formulation. The pharmacokinetic profile of the nanoparticles was not impressive. Only 4% of the recovered dose was found in the tumor, whereas 80% of the recovered dose was detected in the liver 4 h after injection. 17 The transgene expression in the tumor was nevertheless comparable to that in the liver. 8 The results imply that the nanoparticles may be mainly taken up by Kupffer cells in the liver, rather than by hepatocytes. Interestingly, 50% of the tumor cells were transfected, even though only a small portion of the dose had distributed to the tumor. Also, PEGylation of the gelatin nanoparticles did not reduce the transfection activity and gelatin-PEG nanoparticles were more effective than lipofectin in the in vitro transfection experiment. Cationic lipids or polymers can cause structural transition of uncoupled DNA from supercoiled to open circular form at the peri-nuclear region. The open circular plasmid DNA, with a hydrodynamic diameter of 4100 nm, is too large to enter to the nucleus, which has a pore size ranging from 9 to 26 nm.
As there is no charge interaction involved in the gelatin nanoparticles, the released plasmid DNA at the perinuclear region can retain its supercoiled structure 8 and thus has a better chance to enter to the nucleus.
Reduction of the alkyl chain length of the PEG-lipid from C18 to C16 reduced the immune response against PEGylated liposomes Judge et al. 10 developed a PEGylated liposome for systemic administration of plasmid DNA that achieves selective gene expression in tumors. They also found that repeat injection of their delivery system resulted in loss of tumor targeting, accelerated blood clearance and acute hypersensitivity. These effects are due to antibody response against PEG that results from the immunostimulatory effect of the encapsulated plasmid DNA. By using more diffusible PEG-lipids (i.e. lipid with C16 alkyl chain), they minimized the immunogenicity of the lipid vesicle. As the antibody response was against PEG component and required close association with plasmid DNA, the use of rapidly diffusible PEG-lipids may limit the opportunity for anti-PEG responses to develop.
Oligonucleotide/siRNA delivery
As siRNA can silence both exogenous and endogenous genes in mammalian cells, there has been increasing enthusiasm for developing therapies based on RNA interference. Using intranasal delivery, Bitko et al. 18 successfully demonstrated anti-viral activity of naked siRNA in mouse lungs. However, siRNA delivery via systemic routes remains a challenge. 19 mixed 2 0 -O-methyl phosphorothioate (2OMeAO) with Pluronic F127, a commercially available triblock copolymer, and i.v. injected the mixture into mdx dystrophic mice. The antisense oligonucleotide was designed to facilitate skipping of exon 23, which contains the nonsense mutation, in order to restore the reading frame of the dystrophin gene in this murine model of Duchenne's muscular dystrophy. They found that repeated injections Systemically used non-viral vectors S-D Li and L Huang enhanced the dystrophin induction in all skeletal muscles but not in the cardiac muscle. Up to 5% of the normal level of dystrophin was restored after three i.v. injections at weekly intervals. No evidence of tissue damage was detected. Pluronic F127 increases the delivery efficiency of muscle cells by local injection 20 and this is the first report via systemic injection. Although 5% restoration of dystrophin cannot produce any significant therapeutic effect, the formulation might be optimizable.
Cholesterol-modified siRNA showed increased stability and gene silencing activity Chemical modification is the first strategy for siRNA delivery. siRNA was stabilized at the 3 0 end of both strands by phosphorothioate backbone modification and additional incorporation of two 2 0 -O-methyl nucleotide overhangs, and cholesterol (chol) was then linked to the 3 0 end of the sense strand via a pyrrolidine. 21 Chol linkage increased the binding of chol-siRNA to human serum albumin and thus improved the pharmacokinetic properties compared to the unconjugated siRNA when injected systemically. Chol conjugation prolonged the half-life of siRNA from 6 to 95 min, and increased the tissue bioavailability in a variety of organs. The chemically modified siRNA downregulated apolipoprotein B (apoB) mRNA in the liver and the jejunum, decreased plasma levels of apoB protein and reduced the total chol via RNAi-mediated mRNA degradation. Chol, being a highly hydrophobic molecule, not only improved the stability of siRNA in human serum but also increased the lipophilicity and thus enhanced the cellular penetration of the siRNA. However, the lack of tissue specificity is the drawback of this strategy.
Atelocollagen/siRNA complexes showed great antitumor activity via RNAi Atelocollagen, a highly purified type I collagen, was employed to deliver siRNA by Takeshita et al. 22 After being mixed with atelocollagen, siRNA was i.v. injected into mice with bone-metastatic prostate cancer. The complex showed effective reduction in metastatic tumors but did not induce the serum levels of IL-12 and IFN-a. Nevertheless, atelocollagen could not provide tissue targeting for siRNA and delivered siRNA to all major organs.
Protamine-Fab antibody fusion protein delivered siRNA predominantly to target cells and silenced the target genes
Ligand-derived delivery is a well-known method to increase tissue specificity. Song et al. 4 designed a protamine-Fab antibody fusion protein to deliver siRNA to HIV-infected cells or tumor cells. When mixed with the fusion proteins, siRNA could bind with positively charged protamine and conjugated antibody could target the complex to cells that express certain receptors. The results showed that siRNA complexed with the fusion protein was specifically delivered to HIV-envelopeexpressing cells or ErbB2-expressing cancer cells but not to normal tissues after i.v. injection. They also successfully demonstrated the antitumor effect in vivo. Biodistribution and toxicity of the vector still need to be studied.
Targeted, PEGylated polyplexes/ immunoliposomes provided high tumor uptake for siRNA and marked antitumor activity via RNAi A PEGylated form of branched PEI was synthesized with an RGD peptide attached to the distal end of PEG aimed at tumor neovasculature targeting.
11 Targeted polyplexes with a particle size of about 100 nm and zeta potential of 6 mV were prepared by simply mixing polymer and siRNA. When i.v. injected into tumor-bearing mice, the ligand-targeted, PEGylated polyplex increased siRNA uptake in the tumor and decreased uptake in the lung and the liver compared to the 'naked' polyplex. Systemic administration of the targeted formulation induced siRNA sequence-specific inhibition of VEGF in the tumor, resulting in the inhibition of both tumor angiogenesis and growth.
Hu-Lieskovan et al. 12 developed a multicomponent delivery system for metastatic tumor treatment. The system includes a cationic cyclodextrin that can selfassemble with siRNA against EWS-FLI1 to form nanoparticles of 50 nm in diameter, surface decoration of PEG and transferrin protein conjugation to some of the PEG chains. This is the first study to show that systemic administration of siRNA in targeted carriers can downregulate oncoproteins and suppress the spread of metastatic tumors. Additionally, no abnormalities in IL-12 and IFN-a levels, major organ morphologies, or blood counts were observed.
Immunoliposomes were shown to be a powerful carrier to deliver plasmid DNA encoded with an siRNA sequence across the blood-brain barrier (BBB) and target glioma cells by Zhang et al. 6 Two antibodies, transferrin receptor antibody (TfR mAb) and human insulin antibody (HIR mAb), were attached to the PEGylated liposome. When administered i.v. TfR mAb can cross the BBB via transcytosis and HIR mAb can target glioma cells. The immunoliposome markedly downregulated EGFR and significantly prolonged the survival of tumorbearing mice by i.v. injection.
SNALPs targeted to the livers and showed RNAi-mediated gene silencing in hepatitis B and hypercholesteroldemia models
Provita Biotherapeutics has utilized their SNALPs technology to introduce RNAi-based therapeutics on liverrelated diseases, such as hepatitis B and hypercholesteroldemia. 7, 23 They prepared liposomes encapsulating siRNA by mixing lipids (DSPC:Chol:PEG-C-DMA: DLinDMA ¼ 20:48:2:3 molar ratio) in ethanol with an aqueous solution of siRNA in a controlled, stepwise manner. SNALPs were formed after an instantaneous Systemically used non-viral vectors S-D Li and L Huang dilution of ethanol and a second stepwise dilution. Particle size was 140712 nm with a polydispersity of 0.1170.02, and 9373% of the siRNA was found to be encapsulated within the liposomes. After i.v. injection, almost 100% of the injected dose distributed to the livers in guinea-pigs. 24 They encapsulated siRNA targeted to hepatitis B virus (HBV) and examined in an in vivo mouse model for HBV replication. Three daily i.v. injections of 3 mg/kg reduced serum HBV DNA by more than 1.0 log 10 . The reduction in HBV DNA was specific, dose-dependent and lasted for 7 days.
7 SNALPs were also the first non-viral vectors for siRNA showing activity in non-human primates. 23 APOB-specific siRNA encapsulated in SNALPs silenced more than 90% ApoB in cynomolgus monkeys at the i.v. dose of 1 or 2.5 mg/kg. Significant reductions in ApoB protein, serum chol and low-density lipoprotein levels were detected 24 h after treatment and lasted for 11 days.
Inflammatory toxicity of non-viral vectors and management
Certain proteins involved in lung targeting and reduced liver uptake in sequential injection of cationic liposome and plasmid DNA Systemic administration of lipoplexes, the most commonly used non-viral vector, induces a rapid activation of the innate immune system and induces high levels of proinflammatory cytokines, such as tumor necrosis factor-a (TNF-a), interferon (IFN)-g, interleukin (IL)-6, and IL-12. 25 Several studies have demonstrated that the inflammation not only causes systemic toxicity in animals but also leads to a reduced duration of gene expression. 25 Strategies to reduce the inflammatory toxicity can be summarized under three categories: (1) eliminating immunostimulatory CpG motifs in the plasmid DNA; (2) decreasing the interactions of lipoplex with immune cells; and (3) suppressing the immune response to lipoplex by using immunosuppressive agents. 26 Our group previously reported that sequential injection of cationic liposome and plasmid DNA leads to markedly reduced inflammation and improved transfection in the lung. Recently, we discovered that sequential injection (single bolus injection of cationic liposomes and plasmid DNA via the tail vein sequentially with 2 min apart) greatly reduced the DNA uptake in the liver from 35 to 5% of the injected dose, and increased the uptake in the lung from 30 to 70% of the injected dose compared to lipoplex injection. 27 Macrophages are the major source of proinflammatory cytokines in the early immune response and Kupffer cells, the macrophages in the liver, are principally responsible for the lipoplex uptake and the production of a large immune response. Sequential injection dramatically lowers inflammatory toxicity and changes the tissue distribution of plasmid DNA, leading to higher transfection in the lung. We further studied the mechanism by preparing a sequential mimic complex (liposome premixed with serum and then DNA added) and comparing this to a lipoplex-serum mixture. The sequential mimic complex produced 80% lower TNF-a levels and over 10-fold higher transfection activity than the lipoplex in the lungs, consistent with previous data. 28 The two complexes were similar in particle size and protein content but differed in protein composition as shown by 2-D gel electrophoresis. This suggests that certain proteins may alter tissue distribution or facilitate DNA uptake in the lung. Figure 1 summarizes the pharmacokinetic difference between the two complexes and the hypothesis. Our ongoing research is to identify the protein(s) and utilize them to develop a novel lungtargeted vector.
Sequence-dependent stimulation of the immune response by synthetic siRNA can be abrogated by incorporation of 2 0 OMe uridine or guanosine nucleosides into one strand siRNA can be potent triggers for the immune response, particularly when associated with delivery vesicles that facilitate intracellular uptake. Judge et al. 29 identified 0 -UGUGU-3 0 within siRNA as one immunostimulatory motif and showed that the sequence recognition mechanism is stringent enough that minimal base substitution can have profound effects to reduce the immune response. Recently, they showed that immune stimulation by synthetic siRNA can be completely diminished by selective incorporation of 2 0 -O-methyl (2 0 OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. The modified siRNA had full genesilencing activity and was tested in mice without generating cytokine induction, toxicity or off-target effects. 30 
Clinical trials of non-viral-based gene therapy
Intratumoral delivery of IL-2 plasmid DNA showed encouraging results in head and neck cancer patients in a phase I trial O'Malley et al. 31 performed a phase I dose escalation study of IL-2 non-viral gene therapy with advanced head and neck cancer. DMRIE:DOPE cationic liposomes formulated with CMV-IL-2 plasmid were administered intratumorally in the 11-patient trial. At all dose levels from 0.06 to 0.6 mg of plasmid DNA during both the single and multiple dosing regimes (six injections over a 5-week period), therapy was safe and well tolerated. Plasmid DNA was still detectable 7 days after single injection and 14 days after multiple injections. Only 0.019% of the injected dose was detected in the blood 4 h after injection and was undetectable by 28 days. All patients completed the trials, but most patients died of disease progress. One patient in the multiple dosing regimes showed a reduction in tumor burden. Phase II clinical trials will be conducted soon.
Prospects
Some of the prospects speculated in our previous review have been realized in the last 3 years. Optimization of physical techniques for gene delivery is continuing. 32 Immune responses originated from plasmid DNA or siRNA and non-viral vectors were managed as discussed. Several delivery carriers have been developed for systemic administration as described in this review. Novel peptide ligands were developed by in vivo phage display technology and showed specific targeting, 33 and their use for gene delivery is expected soon. The knowledge of plasmid DNA translocation mechanisms within the cells is accumulating. 34 Several tissue-specific and long-term expression plasmid vectors have been developed. 35, 36 Overall, almost all of our predictions have been realized within the last 3 years.
In the last 2 years, investigators have used new technologies to establish efficient and safe non-viral gene delivery by systemic administration. Although significant progress has been made, there is still a long way until the perfect gene carrier can be used clinically. More mechanistic studies must be performed to achieve a better understanding of the delivery barriers in vivo including pharmacokinetics, internalization, intracellular trafficking and DNA release and transcription. New mechanistic insights will lead to the development of more efficient and safer carriers. Advanced technologies, such as RNA aptamer or RNA display, will play a role in the development of targeting ligands with high affinities. 37, 38 RNA aptamers are selected from a library through the binding, recovery and amplification cycle named systematic evolution of ligands by exponential enrichment. 39 In addition to PEGylation, a new approach must be developed to overcome the high RES uptake of the vector in the liver. Despite the fact that much work still lies ahead, a gene carrier suitable for clinical use is on the horizon.
Summary
As the success of gene therapy is highly dependent on the delivery vector, research in this field has been focused on the development of a suitable delivery system. Investigators of non-viral delivery systems have shown marked improvements in efficiency. However, viral vectors remain more efficient delivery vehicles. Over the past decade, studies examining the mechanisms by which viral vectors are proficient at gene delivery have enabled us to further optimize non-viral formulations and move these vectors from local administration to systemic and targeted delivery. Several non-viral delivery systems have been developed which can selectively transfect tumor cells with plasmid DNA by intravenous injection. The discovery of siRNA has also had a strong impact on this field. A variety of nonviral carriers have been developed for targeted siRNA delivery via a systemic route. Finally, the inflammatory toxicity of lipoplex, the most commonly used non-viral vector, has been addressed and managed by using the sequential injection method and formulations containing anti-inflammatory drugs. Exciting progress is being made in the use of systemic non-viral gene therapy.
